Purpose: To assess the effects of treating and side effect of Imatinib (Glivec) in GISTs. Methods and Materials: a prospective clinical interventions in 35 patients with GIST, who had a CD 117 (+) and used Glivec at the nuclear medicine and oncology center - Bach Mai hospital from 4/2012 to 6/2014. Results: Age: Average age was 56.9 years old. Ages at the time of Glivec ranged from 37 (youngest) to 75 (oldest). Rates male/remale: 1.33/1. The primitive tumors appeared at stomach (45,7 percent), small Intestine (25,7 percent). 28 patients use Imatinib (Glivec) 400 mg/day, 1 patient used the dose 800 mg/day because he had the mutation in exon 9. Evaluation after 26 month: 1 patient responded completely; 20 patient partially responded; 12 patients were with a stable disease and 2 patients with a disease's progression. The time Progression-free survival: 18-25 months and the time overall survival: 18-21 months. The side effects of Imatinib (Glivec) was mild, the most common: white skin (68,5 percent); nausea; fatigue (45,7 percent); dermatitis (44,9 percent); conjunctivitis (34.2 percent) and periorbital edema (34.2 percent). The side effect on the heamatological system, liver and kidney are in grade 1. Conclusions: Glivec is safe and effective targeted-drug to treat GIST.
- Đăng nhập để gửi ý kiến